Newsfeeds - Spark Newswire

1 minute read

GlaxoSmithKline Q4 EPS 25.80p Up From 23.60p YoY, Sales £7.38B Up From £7.08B YoY

Today, 4:58 AM

GlaxoSmithKline (NYSE:GSK) reported quarterly earnings of 25.80p per share. This is a 9.32 percent increase over earnings of 23.60p per share from the same period last year. The company reported £7.38 billion in

GSK

5 minute read

February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More

By Shanthi Rexaline

Today, 4:58 AM

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.

APLS

1 minute read

World Organization For Animal Health Says Bolivia Reports Outbreaks Of Highly Pathogenic Bird Flu In Poultry

By Happy Mohamed

Today, 4:58 AM

- Reuters

GNBT

2 minute read

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

By Vandana Singh

Today, 4:58 AM

CureVac N.V. (NASDAQ:CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK…

CVAC

1 minute read

Earnings

GSK Earnings Conference Call Is Coming Up, Here’s What You Need To Know

By Benzinga Insights

Today, 4:58 AM

GSK (NYSE:GSK) will host a conference call at 06:00 AM ET on February 1, 2023, to discuss Q4…

GSK

1 minute read

Jim Cramer Says This Stock Up 23% In A Month Is ‘A Great Speculative Buy’

By Lisa Levin

Today, 4:58 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."

2 minute read

Reported Late Wednesday, WuXi Biologics And GSK Enter Into License Agreement On Multiple Novel Bi- & Multi-specific T Cell Engagers; Wuxi Biologics Will Receive An Upfront Payment Of $40M And Tiered Royalties On Net Sales

By Benzinga Newsdesk

Today, 4:58 AM

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi

GSK

1 minute read

News

Drugmakers To Raise Prices On At Least 350 Drugs In U.S. In January

By Benzinga Newsdesk

Today, 4:58 AM

Drugmakers including Pfizer Inc PFE.N, GlaxoSmithKline PLC GSK.L, Bristol Myers Squibb BMY.N, AstraZeneca PLC AZN.L and Sanofi SA SASY.PA plan to raise prices in the United States on

AZN

1 minute read

News

Czech Veterinary Authority Reports Bird Flu Of H5n1 Type At Poultry Farm With 742,000 Chickens

By Benzinga Newsdesk

Today, 4:58 AM

-Reuters

BBIG

1 minute read

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca

By Vandana Singh

Today, 4:58 AM

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

GSK